To clarify again, cash is $15m. The numbers in the 4C are...

To clarify again, cash is $15m. The numbers in the 4C are irrelevant but there will be more CR to come as this is the nature of bios until they produce income or one-off payments for deals.

The problems aren't the CRs, the problem are the Ts&Cs. PH always blames the market for not valuing CHM correctly and yet he is the one throwing around huge discounts. If JC is telling the truth - and why would she lie - then Hopper needs to go out and try harder to promote CHM, something he hasn't done since the IPO or he isn't capable of as the IPO was done when everyone was throwing cash at any bio without thinking.

Worst case, more CR at the current level until big investors or pharma spot the bargain. So far it looks like the CLTX technology in 1101 and 1301 is the big winner. Sounds a bit strange that Scorpion venoum / Chlorotoxin is the compound that makes the difference but other animal's venoum has proven over thousands of years to have medical benefits. After all it is all about chemistry and the composition of max 92 naturally occurring elements.

Interestingly, CHM 0201 + VACTOSERTIB TRIAL ( at no cost to CHM ), seems to be dead as one poster recently noted. Replaced by the AML trial and upcoming development of

"From the CHM 0201 platform, Chimeric also initiated development and has
recently shown promising preclinical activity of CHM 0301, an armoured next generation NK cell platform
and CHM 1301, an allogeneic CLTX CAR NK."


EV at $5-10m, if I continue to buy maybe I reclaim #2 holder status. Imagine me in the boardroom arguing with Paul - WW3, LOL.

GLTA